EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Inebilizumab treatment in Japanese patients with IgG4-related disease: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE)

Yoshiya Tanaka iD, Hisanori Umehara, Hirokazu Sato, Kosuke Uchima, Kouji Kawai, Kazuichi Okazaki

Modern Rheumatology · 31.08.2026 · 36 (5) · 801-808

DOI: 10.1093/mr/roag020 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Modern Rheumatology, online erschienen am 06.03.2026. Verfasst von Yoshiya Tanaka und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Targeted Therapeutics, First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Immunoglobulin G4-Related Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Tanabe Pharma Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This subgroup analysis of the MITIGATE study aimed to evaluate whether the efficacy and safety of inebilizumab in Japanese patients with IgG4-related disease are consistent with those observed in the overall trial population.

Methods

MITIGATE was a randomized, double-blind, placebo-controlled, phase 3 study conducted in 22 countries, and this subgroup analysis included the Japanese patients enrolled in that trial.

Results

In total, 27 Japanese patients (inebilizumab, N = 20; placebo, N = 7) were included in this subgroup analysis. The organs most frequently affected were the submandibular gland (66.7%), lacrimal gland (59.3%), and pancreas (51.9%). Despite the discontinuation of glucocorticoids within 8 weeks of study initiation, there were no adjudication committee-determined flares requiring treatment in the inebilizumab group. Flares were observed in four patients (57.1%) in the placebo group, with a median time to the first flare of 246.0 days. Inebilizumab reduced the annualized flare rate, increased flare-free complete remission, and lowered glucocorticoid use. Safety profiles were similar between treatment groups; most treatment-emergent adverse events were non-serious.

Conclusions

Inebilizumab reduced flare risk and glucocorticoid exposure, and it was well tolerated in Japanese patients with IgG4-related disease, which is consistent with the overall MITIGATE results.

Trial registration

NCT04540497.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedImmunoglobulin G4-Related DiseaseHumansDouble-Blind MethodFemaleMaleTreatment OutcomeMiddle AgedAgedJapanAdultEast Asian People

Stichwörter der Autor:innen

B-cell depletionIgG4-related diseaseJapanefficacyflareinebilizumabrandomized controlled studysafety

Substanzen

Antibodies, Monoclonal, Humanizedinebilizumab

Autor:innen und Institutionen

  • Department of Molecular Targeted Therapeutics, First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
  • Center for RA and Autoimmune Diseases, Nagahama City Hospital, Nagahama, Japan.
  • Medical Affairs Department, Tanabe Pharma Corporation, Tokyo, Japan.
  • Medical Affairs Department, Tanabe Pharma Corporation, Osaka, Japan.
  • Clinical Science Department, Tanabe Pharma Corporation, Tokyo, Japan.
  • Department of Internal Medicine, Kansai Medical University Kori Hospital, Neyagawa, Japan.

ORCID-Profile: Yoshiya Tanaka

Förderung

  • Tanabe Pharma Corporation

Zitieren

APA

Tanaka, Y., Umehara, H., Sato, H., Uchima, K., Kawai, K., & Okazaki, K. (2026). Inebilizumab treatment in Japanese patients with IgG4-related disease: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE). Modern Rheumatology, 36(5), 801-808. https://doi.org/10.1093/mr/roag020

Vancouver

Tanaka Y, Umehara H, Sato H, Uchima K, Kawai K, Okazaki K. Inebilizumab treatment in Japanese patients with IgG4-related disease: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE). Modern Rheumatology. 2026;36(5):801-808. doi:10.1093/mr/roag020

BibTeX
@article{Tanaka2026,
  author = {Tanaka, Yoshiya and Umehara, Hisanori and Sato, Hirokazu and Uchima, Kosuke and Kawai, Kouji and Okazaki, Kazuichi},
  title = {Inebilizumab treatment in Japanese patients with IgG4-related disease: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE)},
  journal = {Modern Rheumatology},
  year = {2026},
  volume = {36},
  number = {5},
  pages = {801--808},
  doi = {10.1093/mr/roag020}
}
Kostenlos starten →